enVVeno Medical Corporation’s VenoValve: A Game-Changer in Venous Disease Treatment
IRVINE, CA – March 31, 2025 – enVVeno Medical Corporation, a pioneering company in the field of venous disease treatment, announced that an abstract from their research has been accepted for presentation at the Society for Clinical Vascular Surgery (SCVS) 52nd Annual Symposium. Scheduled to take place in Austin, TX from March 29 to April 2, 2025, this esteemed event will feature presentations from leading experts in the field of vascular surgery.
The accepted abstract, titled “Impact of the VenoValve on Patients with Primary and Thrombotic Deep Venous Reflux,” will be presented by Dr. Cassius Iyad Ochoa Chaar, Associate Professor of Surgery at Yale School of Medicine and Principal Investigator of the VenoValve U.S. pivotal trial. The presentation is set for 8:20 AM CT on April 2, 2025.
What is the VenoValve?
The VenoValve is a minimally invasive, transcatheter venous valve replacement system designed to treat deep venous reflux, a common cause of chronic venous insufficiency (CVI). Deep venous reflux occurs when the valves in the deep veins of the legs fail to function properly, allowing blood to flow backward and pool in the legs. This condition can lead to a range of symptoms, including leg pain, swelling, and skin changes, and can increase the risk of developing more serious conditions, such as deep vein thrombosis and pulmonary embolism.
The Impact of the VenoValve on Patients
The abstract accepted for presentation at the SCVS Symposium will highlight the results of the VenoValve U.S. pivotal trial, which enrolled over 300 patients with primary and thrombotic deep venous reflux. Preliminary data from the trial has shown that the VenoValve effectively restores venous valve function and improves symptoms in patients with deep venous reflux. Patients who received the VenoValve experienced significant reductions in leg pain, swelling, and quality of life improvements, as compared to those who underwent standard of care treatment.
The Global Impact of the VenoValve
The successful results of the VenoValve U.S. pivotal trial represent a major breakthrough in the treatment of venous disease. An estimated 1 in 10 adults worldwide are affected by CVI, making it a significant global health issue. The VenoValve offers a minimally invasive, effective solution for treating deep venous reflux, which can help improve the quality of life for millions of people worldwide.
Conclusion
The acceptance of enVVeno Medical Corporation’s VenoValve abstract for presentation at the SCVS Symposium is a testament to the groundbreaking potential of this innovative technology. With preliminary data showing significant improvements in symptoms and quality of life for patients with deep venous reflux, the VenoValve represents a major step forward in the treatment of venous disease. As the global population ages and the prevalence of venous disease continues to increase, the VenoValve has the potential to make a significant impact on the lives of millions of people worldwide.
- enVVeno Medical Corporation announces acceptance of abstract for presentation at SCVS Symposium
- Abstract titled “Impact of the VenoValve on Patients with Primary and Thrombotic Deep Venous Reflux”
- Presentation by Dr. Cassius Iyad Ochoa Chaar on April 2, 2025
- VenoValve is a minimally invasive, transcatheter venous valve replacement system
- Preliminary data shows VenoValve effectively restores venous valve function and improves symptoms in patients with deep venous reflux
- An estimated 1 in 10 adults worldwide are affected by chronic venous insufficiency
- The VenoValve offers a minimally invasive, effective solution for treating deep venous reflux
